Characteristics of BR nonresponders vs responders
| Characteristic . | Responders, n = 165 . | Nonresponders, n = 23 . | P . |
|---|---|---|---|
| CR, n = 103; PR, n = 62 . | PD, n = 23 . | ||
| Age >65 y at BR initiation | 79 (48) | 10 (44) | .692 |
| Male | 105 (64) | 15 (65) | .882 |
| Performance status >1 | 21/135 (16) | 13/21 (62) | <.001 |
| Elevated LDH | 31/124 (25) | 9/15 (60) | .005 |
| Ann Arbor stage III/IV | 143/156 (92) | 22/23 (96) | .506 |
| Marrow/blood involvement | 115 (70) | 16 (70) | .990 |
| B symptoms | 32/156 (21) | 8/23 (35) | .125 |
| Largest mass ≥5 cm | 46/96 (48) | 5/12 (42) | .683 |
| MIPI | |||
| High risk | 13/109 (12) | 8/15 (53) | <.001 |
| Intermediate risk | 33/109 (30) | 4/15 (27) | |
| Low risk | 63/109 (58) | 3/15 (20) | |
| Blastoid/pleomorphic | 7 (4) | 6 (26) | <.001 |
| Median Ki67 (range) | 30 (5-90) | 50 (5-90) | .003 |
| Ki67 ≥30% | 79/149 (53) | 12/21 (57) | .723 |
| Ki67 ≥50% | 32/149 (22) | 12/21 (57) | <.001 |
| Prior observation | 18 (11) | 3 (13) | .726 |
| Prior local therapy | 6 (4) | 0 (0) | 1.0 |
| Median no. of chemotherapy cycles (range) | 6 (2-6) | 3 (1-6) | <.001 |
| ≥6 cycles of chemotherapy | 146 (87) | 8 (35) | <.001 |
| Characteristic . | Responders, n = 165 . | Nonresponders, n = 23 . | P . |
|---|---|---|---|
| CR, n = 103; PR, n = 62 . | PD, n = 23 . | ||
| Age >65 y at BR initiation | 79 (48) | 10 (44) | .692 |
| Male | 105 (64) | 15 (65) | .882 |
| Performance status >1 | 21/135 (16) | 13/21 (62) | <.001 |
| Elevated LDH | 31/124 (25) | 9/15 (60) | .005 |
| Ann Arbor stage III/IV | 143/156 (92) | 22/23 (96) | .506 |
| Marrow/blood involvement | 115 (70) | 16 (70) | .990 |
| B symptoms | 32/156 (21) | 8/23 (35) | .125 |
| Largest mass ≥5 cm | 46/96 (48) | 5/12 (42) | .683 |
| MIPI | |||
| High risk | 13/109 (12) | 8/15 (53) | <.001 |
| Intermediate risk | 33/109 (30) | 4/15 (27) | |
| Low risk | 63/109 (58) | 3/15 (20) | |
| Blastoid/pleomorphic | 7 (4) | 6 (26) | <.001 |
| Median Ki67 (range) | 30 (5-90) | 50 (5-90) | .003 |
| Ki67 ≥30% | 79/149 (53) | 12/21 (57) | .723 |
| Ki67 ≥50% | 32/149 (22) | 12/21 (57) | <.001 |
| Prior observation | 18 (11) | 3 (13) | .726 |
| Prior local therapy | 6 (4) | 0 (0) | 1.0 |
| Median no. of chemotherapy cycles (range) | 6 (2-6) | 3 (1-6) | <.001 |
| ≥6 cycles of chemotherapy | 146 (87) | 8 (35) | <.001 |
Values in the table body are shown as n (%) or n/N (%), unless otherwise stated in row headings. Response assessment was not performed in 2 patients who were excluded.